Last reviewed · How we verify
Treatment with Tookad VTP
At a glance
| Generic name | Treatment with Tookad VTP |
|---|---|
| Also known as | WST09 |
| Sponsor | STEBA France |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Study of the Efficacy, Safety and Quality of Life After TOOKAD® Soluble (VTP) for Intermediate Risk Prostate Cancer. (PHASE2)
- Safety and Tolerability Study Using WST11 In Patients With Localized Prostate Cancer (PHASE1, PHASE2)
- Study of Erectile Dysfunction, Urinary Incontinence and Related QoL After TOOKAD® VTP for Low Risk Prostate Cancer (PHASE4)
- Evaluation of Efficacy of TOOKAD® (VTP) Versus Active Surveillance for Intermediate Risk Localized Prostate Cancer (PHASE3)
- Vascular Targeted Photodynamic Therapy T1a Renal Tumours (PHASE1, PHASE2)
- Study of WST11 in Patients With Localized Prostate Cancer (PHASE2)
- Efficacy,Safety and Quality of Life After TOOKAD® Soluble VTP for Localized Prostate Cancer (PHASE3)
- Study Using WST11 in Patients With Localized Prostate Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |